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Abstract 
 
Members of the RASSF family (RASSF1-10) have been identified as candidate tumour suppressors 
that are frequently downregulated by promoter hypermethylation in cancers. These proteins carry a 
common Ras-association (RA) and SARAH domain (RASSF1-6) that can potentially bind Ras 
oncoproteins and mediate protein-protein interactions with other SARAH domain proteins. However, 
there is a notable lack of comparative characterisation of the RASSF family, as well as molecular and 
structural information that facilitate their tumour suppressive functions. As part of our comparative 
analysis, we modelled the RA and SARAH domains of the RASSF members based on existing 
structures and predicted their potential interactions. These in silico predictions were compared to in 
vitro interaction studies with Ras and MST kinase (a SARAH domain-containing protein). Our data 
shows a diversity of interaction within the RASSF family RA domain, whereas the SARAH domain-
mediated interactions for RASSF1-6 are consistent with the predictions. This suggests that different 
members, despite shared general architecture, could have distinct functional properties. Additionally, 
we identify a new interacting partner for MST kinase in the form of RASSF7. Current data supports 
an interaction model where RASSF serves as an adaptor for the assembly of multiple protein 
complexes and further functional interactions, involving MST kinases and other SARAH domain 
proteins, which could be regulated by Ras.  
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Introduction 
 
The Ras-association domain family (RASSF) comprises of 10 members, known as RASSF1 to 
RASSF10. The RASSF proteins carry several characteristic domains and function as adaptor proteins 
in many important biological processes, such as pro-apoptotic pathways, cell cycle and cytoskeleton 
regulation. Studies have also shown that expression of many RASSF members is downregulated by 
promoter hypermethylation in various types of cancers, including colorectal, lung, breast, prostate and 
brain cancers (Akino et al., 2005; Dammann et al., 2000; Eckfeld et al., 2004). This epigenetic 
silencing of RASSF1 has also been linked to advanced tumour stage and poor prognosis (Pfeifer and 
Dammann, 2005). However, in many cases, over-expression or re-expression leads to cell cycle arrest 
or growth suppression (Burbee et al., 2001; Eckfeld et al., 2004; Ikeda et al., 2007; Vos et al., 2003b). 
When presented together, these characteristics make the RASSF family potential cancer markers and 
tumour suppressors.  
 
The ten RASSF members are divided into two sub-categories: the classical RASSFs (RASSF1-6) and 
N-terminal RASSFs (RASSF7-10) (Fig. 1). All members carry a common Ras-association (RA) 
domain. As the Ras genes are mutated in 20 to 25% of human tumours (Downward, 2003), the RA 
domain and its ability to interact with various Ras GTPases carry particular importance in the RASSF 
tumour suppressor function. Despite this, only the RA domain for RASSF5 has been characterised by 
X-ray crystallography (Stieglitz et al., 2008). It displays the conserved ubiquitin-fold and binds to 
HRas with a sub-micromolar affinity; however, its doubly large size of 160 residues sets it apart from 
other well characterised RA domains, such as that of RalGDS, c-Raf and PLCε (Bunney et al., 2006; 
Huang et al., 1998; Nassar et al., 1996), due to an N-terminal subdomain required to make contact 
with the Ras switch II interface. The high homology amongst RASSF1-6 suggests similar structural 
arrangement and behaviour for these potential Ras effectors. There have been numerous studies 
showing different classical RASSF members binding to various Ras GTPases (Dallol et al., 2009; 
Miertzschke et al., 2007; Rodriguez-Viciana et al., 2004; Stieglitz et al., 2008; Vos et al., 2000). 
However, several of these reports are contradictory (Richter et al., 2009; Rodriguez-Viciana et al., 
2004). Information regarding the RA domain for the N-terminal RASSFs is even scarcer, with only 
two reports of Ras binding by RASSF7 and RASSF9 (Rodriguez-Viciana et al., 2004; Takahashi et 
al., 2011).  
 
Much of the RASSF function in the pro-apoptotic pathway involves the Sav/RASSF/Hippo (SARAH) 
domain (Fig. 1) and its ability to mediate protein-protein interactions. The SARAH domain has been 
shown to facilitate dimerisation between SARAH domain-containing proteins, which allows all the 
classical RASSF members to interact with a family of pro-apoptotic kinases, known as the 
Mammalian sterile 20-like (MST) kinases (Cooper et al., 2008; Hwang et al., 2007; Ikeda et al., 2009; 
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Khokhlatchev et al., 2002; Praskova et al., 2004). The only known structure of the SARAH domain 
comes from MST1 kinase. It consists of two α-helices and forms homodimers or heterodimers with 
RASSF5 via two anti-parallel α-helices (Hwang et al., 2007). It was also reported that the SARAH 
domain has a higher propensity for forming heterodimers compared to homodimers; and more 
recently, this dimerisation helps to stabilise the SARAH domain structure (Constantinescu Aruxandei 
et al., 2011). The ability to oligomerise is crucial for the functions of both MST1 kinase and RASSF, 
the latter of which was shown to enhance MST1 activity to promote apoptosis upon Ras-binding 
(Avruch et al., 2006). The SARAH domain is not present in the N-terminal RASSFs; however, an 
alternative coiled-coil structure has been predicted at the C-terminal region of RASSF7, RASSF8 and 
RASSF10. This could potentially function similarly to the SARAH domain, although there is no 
evidence as yet of interaction mediated by the coiled-coil motif. 
 
Despite numerous studies on the RASSF family in recent years and the increasing evidence 
highlighting their role as potential tumour suppressors, most RASSF members remain poorly 
characterised. There is a notable lack of in-depth, comparative characterisation of the RASSF family 
at the molecular level; information on structure and underlying molecular mechanisms that facilitate 
the RASSF tumour suppressive functions is also scarce. Here, we present a comprehensive 
comparative analysis of the RA and SARAH domains of all the RASSF family members using both in 
silico predictions and in vitro experimentations.  
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Materials and Methods 
 
Cloning, Protein Expression and Purification 
Constructs used for bacterial cell expression were prepared in pTriEx4 (Novagen) as outlined 
(Bunney et al., 2006). The following constructs used in this study were described previously: pTriEx4 
RAPL (RASSF5) SARAH (residues 212-265) (Miertzschke et al., 2007) and HRas G12V (Bunney et 
al., 2006). All constructs above and MST1 SARAHmyc (residues 432-487) were expressed in E. coli 
and purified as described (Miertzschke et al., 2007). For interaction studies, MST1 (residues 1-487), 
MST2 (residues 1-491) and their kinase-dead mutants MST1 K59R and MST2 K56R were cloned 
into pTriEx6 (Novagen) with an additional myc tag. Other constructs used were cloned into pEGFP-
C1 (Clontech) and pTagRFPT-C1, which were converted to Gateway compatible vectors. pTagRFPT-
C1 was derived from pEGFP-C1 by swapping the fluorophores using restriction digests and ligation at 
the NheI and BglII sites. All RASSF5 constructs used in this study were derived from the RASSF5C 
isoform, which is identical to RASSF5A in the RA and SARAH domain regions. All mutagenesis was 
carried out using the QuickChange Site-Directed Mutagenesis Kit (Stratagene), following the 
manufacturer’s instructions. All constructs were verified by sequencing. 
 
Protein Modelling  
The sequences encoding the RA domain and SARAH domain were predicted using PROSITE. For 
RASSF1-4 and RASSF6, the RA domain sequences were aligned to the template of RASSF5 
(NORE1) RA domain (PDB: 3DDC) excluding the N-terminal subdomain (residues 274-358). The 
sequences of the predicted RA domain for RASSF7-9 were aligned to c-RAF RBD (PDB: 1GUA). 
All RA domain alignments were performed and 3D models generated and evaluated as described 
(Miertzschke et al., 2007). The SARAH domains of RASSF1-6 were aligned to the template of MST1 
kinase SARAH (PDB: 2JO8) using Prosite multiple sequence alignment. The 3D models were 
constructed using Modeller v9.8 (Eswar et al., 2006). 100 dimer models were calculated and the 
chosen model for each RASSF represents the best model with the lowest objective function. RASSF7 
coiled-coil models were constructed de novo using Quark online server (available on World Wide 
Web) (Xu and Zhang, 2012). The models were evaluated and validated using the same method as 
above. 
 
In vitro Pull-Down Assays 
The in vitro pull-down assays were carried out as described by Miertzschke et al. (2007) with a few 
minor adjustments. Full length RASSFs, which could not be purified, were each expressed in 30ml 
Freestyle 293F cell cultures as described (Bunney et al., 2012), but in a linearly scaled-down system. 
Each culture was transfected with 37.5µg of pEGFP-C1 RASSF construct. Cells were harvested after 
72 hours and lysed in modified Nonidet P-40 lysis buffer (0.1% Nonidet, 25mM Tris-HCl pH7.5, 
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150mM NaCl, protease inhibitor) for 15 minutes at 4°C. The cell lysates were incubated with 
immobilised S-tagged small GTPases loaded with nucleotide for 1 hour at 4°C with constant agitation 
and washed three times with Nonidet P-40 buffer. For pull-down assays of SARAH domain proteins, 
50µg of immobilised S-tagged RASSF5 SARAH was incubated with 50µg MST1 SARAHmyc for 1 
hour with constant agitation. The beads were washed three times with phosphate-buffered saline. 
Protein-protein interactions were analysed by SDS-PAGE stained with Coomassie blue or by Western 
blotting with anti-GFP (B2) antibody (Santa Cruz).  
 
Co-immunoprecipitation (Co-IP) 
293F cells were co-transfected with different DNA constructs (19µg/ construct) in 30ml cultures and 
lysed after 72 hours in CellLytic M Cell Lysis Reagent (Sigma). The cell lysates were incubated with 
anti-c-myc agarose affinity gel antibody (Sigma) for 1 hour at 4°C with constant agitation and washed 
five times with phosphate-buffered saline. Protein-protein interactions were analyzed by Western 
blotting with anti-GFP (B2) (Santa Cruz), anti-tRFP (Evrogen) and anti-myc (in-house) antibodies. 
 
Mass Spectrometry (MS) 
Mass spectrometry experiments were carried out on a first-generation Synapt HDMS (Waters Corp., 
Manchester, UK) Quadrupole-TOF mass spectrometer (Pringle et al., 2007). Samples were buffer 
exchanged into 150mM ammonium acetate using Biospin-6 columns (Bio-Rad). For the mixing 
experiment, equal-molar of MST1 SARAHmyc and RASSF5 SARAH were incubated for 1 hour at 
4°C prior to MS analysis. 2.5µl aliquots of the protein sample of 15µM in concentration were 
introduced to the mass spectrometer by means of nano-electrospray ionisation using gold-coated 
capillaries prepared in-house. The instrument was mass calibrated using a 33µM solution of Cesium 
Iodide in 250mM ammonium acetate. Typical instrumental parameters were as follows: capillary 
voltage 1.0 kV, cone voltage 50 V, trap energy 6 V, transfer energy 4 V, bias voltage 2.0 V, and trap 
pressure 8.6e^-3 mbar.  
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Results and Discussion 
 
RA domain and its interaction with Ras GTPases 
Modelling the RASSF RA domain and predicting its interactions 
Several approaches have been used to model protein domains in order predict new protein 
interactions. Kiel et al. (2007) used a sophisticated method involving various protein design 
algorithms to draw network interactions between different Ras GTPases and putative Ras-binding 
domains (RBDs). There is no structural distinction between RA and RBD, which are only different 
names used for the same ubiquitin fold. The same study also highlighted the significance of amino 
acid conservation on the protein surface in determining interaction. As general electrostatic 
interactions are important in Ras/ RA binding due to the highly negatively charged surface on the Ras 
switch I and II regions (Kiel et al., 2004; Nassar et al., 1996), an overall positive charge of the RA 
domain surface would suggest that one of the key criteria for Ras binding is fulfilled. However, as 
also shown by structurally characterised RA or RBD domains, such as RASSF5, RalGDS, c-Raf and 
PLCε (Bunney et al., 2006; Huang et al., 1998; Nassar et al., 1996; Stieglitz et al., 2008), residues 
directly involved in interactions with Ras switch I and II regions are difficult to predict.  
 
In order to further understand the RA domain of the remaining RASSF members and its potential 
interactions with Ras GTPases, we employed a simpler approached previously used by Miertzschke et 
al. (2007) to model their RA domain against templates of structurally known RA domain (Fig. 2). We 
first performed a sequence alignment of the classical RASSF members RA domain with the only 
structurally known RASSF RA domain, RASSF5 (Fig. 2A). Only the RA domain sequences predicted 
by Prosite were used for alignments and modelling, which excludes the N-terminal subdomain and β1 
strand of the RASSF5 template. The main residues involved in electrostatic interactions are found in 
β2 and the C-terminus of α1. Several key residues, such as P278, K303 and F304 are highly 
conserved. However, other important residues in β2 aligning to D280, I281, K282 and Q283 are not 
as well conserved, with RASSF1 sharing the most conserved residues with RASSF5.  
 
For each RASSF model, the alignments were manually adjusted to obtain the optimal fit. Due to the 
exclusions we made to the template, β2 in our models, including the remodelled RASSF5 template 
(Supplementary Fig. 1A), is not seen as a strand due to its anti-parallel position with β1 in the original 
RASSF5 template. In the RASSF2, RASSF4 and RASSF6 models, β4 is also missing due to the gap 
aligning to that region (Fig. 2A). Despite several differences in the key interacting residues, there are 
no major changes in the electrostatic surface for all models in the regions of β2 and α1, with the 
exception of RASSF3, which appears to have a neutral surface around the β2 region (Fig. 2B). 
However, theoretically, these changes should not affect Ras interaction of most of the classical 
RASSF members as they are not within the interacting surfaces.   
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A different RBD, c-Raf RBD, was used as a modelling template for the N-terminal RASSF members. 
Fig. 2C shows good alignment between c-Raf and RASSF7 and RASSF8 where most key interacting 
residues in β1 and β2, such as R59, Q66, R67 and V69, are conserved. RASSF9 RA domain amino 
acid residues are not as well conserved in comparison, with only a conserved and a semi-conserved 
residue at the positions of V69 and R67. Unlike the classical RASSF members, the residues aligning 
to the α1 region are not well conserved.  
 
These differences observed in the alignments are evident in the three dimensional models (Fig. 2D). 
For RASSF7 and RASSF8, there are no major electrostatic surface changes in the β1 and β2 regions. 
However, the α1 region, which is highly positively charged in c-Raf (Supplementary Fig. 1B), is now 
neutral. This change is more significant for RASSF9, where the β2 region appears more negatively 
charged. The electrostatic potential changes observed in RASSF7 and RASSF8 may not completely 
eliminate their ability to interact with Ras, but may serve to weaken this interaction.  
 
Overall, the models suggest a high possibility of Ras interaction for all the classical RASSF members 
apart from RASSF3, and two N-terminal RASSF members RASSF7 and RASSF8. Whereas the 
reversal of electrostatic potential in the main interaction surfaces of RASSF9 suggests a non-binder. 
The RA domain of RASSF10 could not be properly aligned and modelled against any known RA 
domain, thus, its Ras interaction could only be determined experimentally. 
 
RA domain of RASSF1-10 shows differential Ras interactions 
Apart from RASSF5, several studies have reported the interaction of different classical RASSF 
members with various Ras GTPases and even Ran GTPase. However, many of the in vitro 
interactions observed are ambiguous and the methods used to show interaction were widely different.  
 
In order to test the in silico predictions and determine whether the predicted RASSF RA domains are 
able to bind Ras, we performed an in vitro pull-down for the whole panel of RASSF family using 
activated HRas G12V. RASSF5 essentially served as a positive control. We show GTP-dependent 
binding to HRas by RASSF3, RASSF4 and RASSF6 from the classical subgroup and RASSF7 from 
the N-terminal subgroup (Fig. 3A). It should be noted that the pull-down method used in this study 
typically detects binding affinities of up to a dissociation constant (kD) of 10µM (Bunney et al., 2006). 
Protein interactions with a high kD (weak binding) or fast off rates (koff) will be impossible to detect 
using such method.  
 
These observations demonstrate that surface electrostatic potential predictions are informative and 
true to a certain extent but insufficient to determine definite interactions. This is evident when the in 
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silico predictions are compared to the in vitro results. RASSF1, which interaction surface and residues 
most resemble RASSF5, and RASSF2, which also has a similar surface potential, did not interact with 
HRas or KRas G12V (not shown). In addition, despite both having a similar positively charged 
surface, RASSF4 proved to be a much weaker binder compared to RASSF6. They also showed 
differential binding to KRas (data not shown): weak binding for RASSF4 and no binding for 
RASSF6. Conversely, RASSF3, which shared minimal conserved residues with RASSF5 and had a 
more neutral binding interface, was the unexpected binder to both HRas and KRas, albeit a weak one 
(data not shown).  
 
The predictions for the N-terminal RASSF members appear slightly more accurate. The GTP-
dependent binding of RASSF7 to HRas, KRas and NRas (data not shown) is in agreement with a 
recent report of NRas interaction (Takahashi et al., 2011). Also true to prediction is RASSF9, which 
had a negatively charged surface, thus did not show any binding. However, it is also puzzling that 
RASSF8, which displays almost identical surface potential and conserved residues to RASSF7, did 
not bind any GTPases.  
 
RASSF5 and RASSF7 are to be the most consistent Ras binders compared to the remaining RASSF 
members. Comparison of our data with existing reports suggests the RA domain may have different 
affinities for different Ras GTPases, such as the reported specificity of RASSF1 for Ran GTPase 
(Dallol et al., 2009). However, some of our observations are contradictory to previous findings, such 
as the KRas specificity of RASSF2 (Vos et al., 2003a), RASSF4 (Eckfeld et al., 2004) and RASSF6 
(Allen et al., 2007), and the only report to date of Ras interaction by RASSF9 (Rodriguez-Viciana et 
al., 2004). In addition, a strongly positively charged surface does not always signify a strong binder, 
as demonstrated by our in vitro pull-down. The differences between previous studies and our data 
could be due to different experimental conditions, Ras specificity, binding affinities and the 
requirement of a third binding partner, such as that reported by Ortiz-vega et al. (2002), or other 
regions of the RASSF proteins in addition to the predicted RA domain, such as an equivalent to the N-
terminal subdomain in RASSF5 (Stieglitz et al., 2008).  
 
SARAH domain and its ability to mediate oligomerisation 
Modelling the RASSF SARAH domain and predicting its interactions 
To date, only the SARAH domain from MST1 kinase has been structurally resolved by Hwang et al. 
(2007). The study demonstrated the significance of hydrophobic interactions mediated by a network 
of non-polar amino acid residues in facilitating homodimerisation and heterodimerisation as well as 
maintaining the stability of the dimers. The SARAH domain is found in all six members of the 
classical RASSF subgroup. However, structural information regarding the RASSF SARAH domain 
remains scarce despite various reports on heterodimerisation between MST kinase and different 
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classical RASSF members and the integral role it plays in the biological functions of the RASSF 
family. The RASSF SARAH domain has never been modelled. It is not known whether the critical 
residues involved in oligomerisation are present in the SARAH domain of all the classical RASSF 
members. 
 
In this study, we aligned the RASSF SARAH domain sequences predicted by Prosite with the 
structurally known MST1 kinase SARAH domain and modelled each RASSF SARAH using these 
alignments. The sequence alignments show a high level of conservation of most residues involved in 
maintaining dimer stability (Fig. 4A). Most residues involved in hydrophobic interactions (L444, 
L451, L448, I459, I462 and Y466) are very well conserved except M455. The two residues involved 
in electrostatic interaction are D452 and R470; the first is conserved only in RASSF3 and RASSF5, 
but the latter appears very well conserved. The physico-chemical properties of the residues aligning to 
those involved in stabilising the H1 and H2 helices in MST1 monomer (L436, W439, V441, L444, 
I473 and I477) are generally conserved, thus still allowing for hydrophobic interactions.  
 
Dimeric SARAH domain models were constructed for each of the classical RASSF member. Fig. 4B 
shows the best model out of the 100 dimer models calculated for each RASSF. The distribution of the 
hydrophobic residues along helix H2 is very similar across all six RASSF members and is also 
comparable to that of MST1 kinase (Supplementary Fig. 1C). Despite the poor conservation of 
residues aligning to D452, the models suggest electrostatic interactions with the second helix H2 are 
still possible due to the presence of a stretch of acidic residues between the regions aligning to L451 
and I459. Based on the conservation of the main features involved in dimerisation, we predict that all 
six classical RASSF members will be able to homodimerise and heterodimerise with MST kinases. 
 
The SARAH domain is notably absent from the N-terminal RASSF members. However, coiled-coil 
domains have been predicted for RASSF7, RASSF8 and RASSF10 (Fig. 1) and this motif is known to 
facilitate oligomerisation (Lupas, 1996). As the C-terminus of the SARAH domain also displays 
relatively high coiled-coil propensity and characteristics (Scheel and Hofmann, 2003), it is possible 
that the coiled-coils predicted for the N-terminal RASSF members could behave similarly to the 
SARAH domain and mediate homotypic or heterotypic interactions.  
 
SARAH domain mediates dimerisation between RASSF and MST kinases 
Hwang et al. (2007) were the first to elucidate the structure of a SARAH domain and demonstrate 
homodimerisation of the MST1 kinase SARAH domain as well as its heterodimerisation with 
RASSF5 in a 1:1 stoichiometry. Various studies have also shown heterodimerisation between MST 
kinases and RASSF1 (Dittfeld et al., 2012), RASSF2 (Cooper et al., 2009), RASSF5 (Khokhlatchev et 
al., 2002) and RASSF6, leading to pro-apoptotic effects (Ikeda et al., 2009). Interestingly, RASSF1 
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was also reported to heterodimerise with RASSF5 to facilitate the tumour suppressor function of the 
latter (Macheiner et al., 2009). However, these interactions have not been compared across the entire 
RASSF family to determine whether all the predicted SARAH domains behave similarly. 
 
In the majority of the dimerisation studies using co-expression in cells, we used kinase-dead MST 
mutants, MST1 K59R and MST2 K56R due to their consistent and higher expression levels. First, we 
compared RASSF5 dimerisation with wild-type and kinase-dead MST1 and MST2. RASSF5 co-
immunoprecipitated equally with all four types of MST kinases tested (Fig. 5A) but the SARAH 
deletion mutant RASSF5Δ213-265 did not (Fig. 5B). This confirmed that the kinase activity does not 
interfere with dimerisation and the RASSF SARAH domain is crucial for interaction.  
 
In the following co-immunoprecipitation assay, the complete panel of all ten RASSF members were 
tested for their interaction with MST1 and MST2. All classical RASSF members co-
immunoprecipitated with MST1 (Fig. 5C, left). A similar interaction pattern is observed with MST2, 
with the exception of RASSF1 (Fig. 5C, right). This varied detection of RASSF1 between the two 
MST kinases could be due to lower expression levels of RASSF1 and MST2 when co-expressed, 
rather than a difference in its interaction with MST1 and MST2. We also show, for the first time, 
interaction between RASSF7 and both MST1 and MST2.  
 
A negative control experiment in which MST was not immunoprecipitated showed negligible 
precipitation of RASSF5 and RASSF7, which confirmed that the RASSF7 interaction observed was 
not a false positive (Fig. 5Da). Since the SARAH domain is absent in RASSF7, we looked at its two 
predicted coiled-coil regions, termed here as coiled-coil 1 and coiled-coil 2. De novo protein structure 
predictions were performed on the two sequences since they do not align well to any known 
templates. Both regions are predicted to form a single helical structure rich in amino acids with 
aliphatic side chains (Fig. 5Db), which implies a high probability of a hydrophobic core to facilitate 
dimerisation.  
 
In addition, we also compared interactions of the isolated SARAH domains in vitro and in a cell 
context. In an in vitro pull-down using purified SARAH domain proteins, MST1 SARAHmyc did not 
interact with immobilised S-RASSF5 SARAH (Supplementary Fig. 2A). We also did not detect any 
heterodimers when these two proteins were mixed and subjected to mass spectrometry (MS) 
(Supplementary Fig. 2B, bottom spectrum). However, monomers and homodimers were detected with 
sizes identical to those for MST1 and RASSF5 SARAH individually (Supplementary Fig. 2B, top, 
middle spectra and table). In contrast, co-immunoprecipitation analysis shows that the RASSF5 
SARAH domain was able to heterodimerise with both full length MST1 and the MST1 SARAH 
domain in a cell context (Supplementary Fig. 2C).  
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Our experimental observations match well with the in silico predictions of the RASSF SARAH 
domain interactions. All six classical RASSF members were able to heterodimerise with the MST 
kinases. Although not tested in this study, there is a high probability of homotypic and heterotypic 
interactions within the RASSF family itself based on the high accuracy of the models and predictions. 
The difference observed in heterodimerisation for the isolated SARAH domain between in vitro and 
in cells, with the specific example of RASSF5, suggests a higher natural propensity for the SARAH 
domain to homodimerise and heterodimerisation may not be preferred in some instances. 
Furthermore, heterotypic interactions may require specific conditions and factors found in cellular 
systems or additional interaction sites outside the SARAH domain. 
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Conclusion  
 
To date, many studies have suggested that Ras-binding and dimerisation of RASSF, mediated by the 
RA and SARAH domains respectively, facilitate its anti-tumourigenic functions (Richter et al., 2009). 
However, functional links of RASSF, Ras and other SARAH domain-containing proteins are not 
clear, with such direct interactions defined only for RASSF5 (Hwang et al., 2007; Stieglitz et al., 
2008). 
 
Both in silico predictions and in vitro experimentations of the RA domain are important in the study 
of its binding characteristics in different RASSF members. The difficulty in expressing the proteins 
for the individual RA domains remains a major hurdle in studying the properties of the isolated RA 
domains. Current data suggests differential binding characteristics for each RA domain despite certain 
shared conserved residues and architecture. However, negative detection of binding for specific 
RASSF members in this study should not rule out possible interactions with different Ras GTPases 
due to a broad range of factors and conditions that could affect such interactions. 
 
The analysis of the SARAH domain was much easier in comparison. This was in part due to good 
alignments and amino acid residue conservation, hence simpler modelling and predictions. 
Experimental data supports, and even exceeds our predictions as we identify new interaction pairs 
between RASSF7 and both MST1 and MST2. However, conditions required for heterodimerisation 
and the region in RASSF7 that mediates this interaction remain to be further clarified.  
 
Based on our current understanding of the RA and SARAH domains, we propose a model for the 
assembly of signalling complexes involving the RASSF proteins (Fig. 6). Interactions between the RA 
domain and members of the Ras GTPase family could result in the translocation of the SARAH 
domain complexes to the membrane and provide an integrative platform for the assembly of larger 
complexes and/ or further functional interactions. The consequences of Ras-binding could also 
involve conformational changes that influence SARAH-mediated dimerisation, consequently the 
regulation of SARAH-domain proteins, such as the MST kinases.  
 
Further interaction and structural studies will provide a greater understanding on the molecular 
properties of the RASSF family. These insights will also reinforce our proposed model of interactions 
and underline the significance of specific protein-protein interactions in driving the potential tumour 
suppressor properties of RASSF.  
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Figure Legends 
 
Figure 1 Schematic representation of the RASSF family  
There are many splice variants of the RASSF members. The most common one has been selected for 
each member and two for RASSF5: RASSF5A and RASSF5C, also known as RAPL. The classical 
RASSF1-6 are on the left and the N-terminal RASSF7-10 on the right. Characteristic domains shown 
are the Protein Kinase C conserved region, C1 (grey), the Ras-association domain, RA (green), the 
Sav-RASSF-Hpo domain, SARAH (blue) and the coiled-coil regions (orange).  
 
Figure 2 Modelling the RASSF RA domain and predicting its interactions 
(A) Multiple sequence alignment of the RA domain of RASSF1-6 predicted by Prosite. Secondary 
structural elements are indicated above. The residues in RASSF5 involved in electrostatic 
interactions with Ras are marked with an asterisk (*) above and the conserved residues aligning to 
those positions are highlighted in grey. Other residues are coloured according to their similarity, 
fully conserved residues in red, highly similar residues in green and weakly similar residues in 
blue.  
(B) Ribbon representations show the classical RASSF RA domain modelled against RASSF5 (PDB: 
3DDC). Side chains of the conserved residues aligning to those in RASSF5 involved in 
electrostatic interactions are in pink and labelled. The surface electrostatic potential is 
superimposed; positively charged regions are in blue and negatively charged regions in red.  
(C) Multiple sequence alignment of the RA domain of the N-terminal RASSF7-9 and c-Raf RBD. 
Secondary structural elements and conserved residues are labelled and highlighted as in (A).  
(D) Ribbon representations show the N-terminal RASSF7-9 RA domain modelled against c-Raf RBD 
(PDB: 1GUA) are presented and labelled as in (B).  
 
Figure 3 RA domain of RASSF1-10 shows differential Ras interactions 
Pull-down analysis of GFP-RASSF1-10 in cell lysates binding to immobilised activated HRas G12V 
loaded with GDP (D) or GTP (T). The lower panels are Ras and RASSF loading controls, and the 
GAPDH endogenous control. 
 
Figure 4 Modelling the RASSF SARAH domain and predicting its interactions 
(A) Multiple sequence alignment of the SARAH domain of MST1 kinase and RASSF1-6. The 
secondary structural elements are indicated as helix 1 (H1) and helix 2 (H2). Residues in MST1 
involved in electrostatic interactions are marked with an arrow head (^), hydrophobic interactions 
for monomer stability with a dot (.) and for dimer stability with an asterisk (*). Conserved 
residues aligning to the positions marked with . or * are highlighted in grey. Residues in red are 
fully conserved, green highly similar and blue weakly similar.  
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(B) Ribbon representations show the classical RASSF SARAH domains modelled against MST1 
kinase (PDB: 2JO8). Basic residues are in blue, acidic in red, polar in white and hydrophobic in 
yellow. Side chains of hydrophobic residues involved in dimer stability are shown in yellow and 
labelled.  
 
Figure 5 SARAH domain mediates dimerisation between RASSF and MST kinases 
(A) Co-IP analysis of GFP-RASSF5 interacting with myc-MST1, myc-MST2 or their kinase-dead 
mutants K59R and K56R respectively. Anti-myc antibody was used to immunoprecipitate (IP) 
MST and their interaction with GFP-RASSF5 was detected by immunoblotting (IB).  
(B) Co-IP analysis of wild-type (WT) GFP-RASSF5 or RASSF5 SARAH domain deletion (Δ213-
265) and myc-MST mutants is on the left. The RASSF5 loading control and GAPDH endogenous 
control are on the right.  
(C) Co-IP analysis of GFP-RASSF1-10 interacting with myc-MST1 K59R (left) or myc-MST2 K56R 
(right). The RASSF and MST loading controls and GAPDH endogenous control are shown below 
the co-IP panels for each set of cell lysates. 
(D) Analysis of RASSF7 interaction with MST. (a) Co-IP analysis of GFP-RASSF5 or RASSF7 and 
myc-MST1 K59R. A simultaneous negative control was performed without the anti-myc 
antibody.  The RASSF loading control and GAPDH endogenous control are on the right. (b) 3D 
models of the two coiled-coil regions of RASSF7 predicted by Prosite. The residues are labelled 
as in Fig. 3B and side chains of hydrophobic residues on the same face of the helix are shown in 
yellow.  
 
Figure 6 Schematic model of interaction between the RASSF family and MST kinases 
The Ras GTPase family is shown as cyan boxes that bind to the RA domain of different RASSF 
members represented by the ubiquitin-fold ribbon structure in blue and yellow. The SARAH domains 
are shown as anti-parallel helices from different RASSF members or MST kinase, in purple and 
green. The ability of the SARAH domain to mediate protein-protein interactions could be a basis for 
the formation of (A) homodimers between two different RASSF members or (B) heterodimers 
between RASSF members and other SARAH domain-containing proteins such as MST kinases. These 
interactions could be regulated by Ras interaction with the RA domain. 
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Supplementary Data 
 
Supplementary Figure 1 3D models of RASSF5 RA and c-Raf RBD  
(A) The ribbon representation of RASSF5 RA domain (residues 274-357) is derived from the PDB 
structure 3DDC. Residues involved in electrostatic interactions with Ras are highlighted in pink 
and labelled. The surface electrostatic potential is superimposed on the model with positively 
charged regions in blue and negatively charged regions in red.  
(B) The ribbon representation of c-Raf RBD (PDB: 1GUA). Residues involved in electrostatic 
interactions with Ras are in yellow and labelled. The surface electrostatic potential is shown as in 
(A). 
(C) The ribbon representation of the MST1 kinase SARAH domain (PDB: 2JO8). Basic residues are 
in blue, acidic in red, polar in white and hydrophobic in yellow. Side chains of the hydrophobic 
residues involved in dimer stability are shown in yellow and labelled.  
 
Supplementary Figure 2 Analysis of the interaction between isolated SARAH domains  
(A) Pull-down analysis of purified protein of MST1 SARAHmyc binding to immobilised S-RASSF5 
SARAH.  
(B) Mass spectra of MST1 SARAHmyc and RASSF5 SARAH proteins under native MS conditions. 
From top to bottom: mass spectrum of MST1 SARAHmyc, RASSF5 SARAH and MST1 
SARAHmyc mixed with RASSF5 SARAH. Charge states corresponding to MST1 SARAHmyc 
monomer, dimer, and RASSF5 SARAH monomer and dimer, are indicated and coloured in red 
and blue, green and cyan, respectively. The table below compares the protein monomeric and 
dimeric mass measurements to the theoretical masses. The low error confirms the accuracy of the 
experimental results. 
(C) Co-IP analysis of TagRFPT-MST1 SARAH and myc-RASSF5 SARAH, in which full length (FL) 
MST1 served as a positive control.  
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